A Lean, Virtual Approach to Complex Pharmaceuticals
Talos Pharma is dedicated to enhancing global healthcare by developing high-quality, affordable generic products with high barriers to entry, focusing on capital efficiency and strategic partnerships.
$728B
Global Generic Market by 2034
CAGR: 5.04%
$231.69B
U.S. Generic Market by 2034
CAGR: 5.24%
$142.89B
U.S. Injectables Market by 2034
CAGR: 14.2%
$33.51B
U.S. Ophthalmics Market by 2033
CAGR: 7.6%
The Market Opportunity
The global generic drugs market is experiencing robust growth, driven by patent expirations of high-cost branded drugs and an increasing global demand for affordable healthcare solutions. Complex generics represent a particularly high-growth segment within this market.
Source: Business Plan Market Analysis
The Virtual Business Model
Our capital-efficient virtual model eliminates the overhead of in-house manufacturing. We focus on expert oversight and strategic management of our world-class CDMO and CRO partners, ensuring quality and agility.
(Expert Oversight)
CDMO Partners
Manufacturing & Scale-up
CRO Partners
Clinical & BA/BE Studies
Regulatory Bodies
Filings & Compliance
Supply Chain
API Sourcing
Product Pipeline
Our pipeline focuses on products with high barriers to entry, ready for technology transfer to our CDMO partners.
An Attractive Financial Model
Lean Per-Product Investment
Our virtual model streamlines costs by focusing capital on value-driving activities like asset acquisition and regulatory approval, not on building and maintaining infrastructure. This de-risks investment and accelerates the path to profitability.
Product Asset Acquisition: $300K
CDMO Partnership: $2-3M
Clinical Studies (CRO): $2-5M
Regulatory & IP Strategy: $600K+
Illustrative Per-Product Cost Allocation
Expert Leadership
Our success is driven by a lean, experienced management team with deep expertise in pharmaceutical development, regulatory affairs, quality assurance, and strategic operations within a virtual model.
CEO
CSO
COO
Regulatory
CFO
Quality